收音像受体4:肥胖和代谢疾病之间的潜在联系
Ghadeer Alhamar1, Joanna Razafiarison2, Fawaz Alzaid2,3
1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait.
概括
肥胖会引发慢性炎症,增加代谢疾病的风险. 收费类受体4 (TLR4) 在这种与肥胖相关的炎症中起着关键作用,这表明它是治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢性疾病研究研究
- 肥胖研究 肥胖研究
背景情况:
- 肥胖是代谢疾病的主要危险因素.
- 将肥胖与代谢功能障碍联系在一起的确切机制尚未完全理解.
- 来自脂肪组织的慢性低度炎症是拟议的联系.
研究的目的:
- 审查托尔类受体4 (TLR4) 在肥胖引起的炎症中的作用.
- 探索TLR4对2型糖尿病 (T2D) 等代谢障碍的贡献.
- 突出TLR4作为一个潜在的治疗目标.
主要方法:
- 对TLR4.4最新研究的文献综述.
- 对研究TLR4在炎症,脂肪生成和新陈代谢中的作用的分析.
- 检查TLR4与肥胖症内毒素的相互作用.
主要成果:
- TLR4参与调节炎症,脂肪生成,热生成和葡萄糖代谢.
- 在肥胖中增加TLR4表达与被破坏的代谢过程有关.
- TLR4信号传递有助于代谢炎症和2型糖尿病的发展.
结论:
- TLR4是肥胖相关代谢炎症的中心调解者.
- 准TLR4及其通路可能为治疗与肥胖相关的代谢疾病提供策略.
更多相关视频
10:40Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
83.0K
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
26.0K
相关概念视频
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Insulin: The Receptor and Signaling Pathways
3.6K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.6K
Overview of Lipid Metabolism
5.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
5.7K
PI3K/mTOR/AKT Signaling Pathway
5.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
